TOG Review (RCOG Journal)
MRCOG Part 2
Maternal Medicine
Insulin pumps and pregnancy
Key Statistics
- 6% vs 40% — UK vs USA pump use, T1DM
- ~20% — UK pregnant pre-existing DM on CSII
- ↓50%↑ — Basal rate rise after 16WK
Don't-miss facts
-
Pumps hold rapid-acting insulin only – disconnection/malfunction → rapid risk of DKA (no long-acting insulin on board)
-
NICE: offer CSII if MDI fails without significant disabling hypoglycaemia; CGM not routine – only for severe hypoglycaemia/unstable/variable glucose
-
Basal rate: ↓ at 8–16 weeks, then ↑ ~50%; carb:insulin ratio ↓ 4-fold mainly after 16 weeks
-
Two meta-analyses show no clear advantage of CSII over MDI in pregnancy outcomes – likely selection bias in trial cohorts
-
Preconception: HbA1c target <48 mmol/mol, avoid conception if >86 mmol/mol; folic acid 5 mg; retina before conception
-
If admitted antenatally with functioning pump – leave it running, involve inpatient diabetes team
-
Labour: continue CSII only if stable control + trained support present, else start IV insulin per local protocol
-
Postpartum: reduce to pre-pregnancy insulin dose immediately after placental delivery; watch for hypoglycaemia with breastfeeding
Pump use by country (T1DM)
UK ~6% Europe >15% USA ~40%
Abbreviation Key
- CSII — continuous subcutaneous insulin infusion (insulin pump)
- NICE — National Institute for Health and Care Excellence
- MDI — multiple daily injections
- DAFNE — Dose Adjustment For Normal Eating (structured carbohydrate-counting education)
- T1DM — type 1 diabetes mellitus
- DKA — diabetic ketoacidosis
- T2DM — type 2 diabetes mellitus
- GDM — gestational diabetes mellitus
- HbA1c — glycated haemoglobin
Source: Insulin pumps and pregnancy. The Obstetrician & Gynaecologist 2016;18:199–203. doi:10.1111/tog.12268
MRCOG AI is an independent educational tool. It is not affiliated with, endorsed by, or connected to the Royal College of Obstetricians and Gynaecologists (RCOG).